Skip to Content

Chromium picolinate / inulin Disease Interactions

There are 4 disease interactions with chromium picolinate / inulin:

Major

Laxatives (applies to chromium picolinate/inulin) inflammatory bowel disease

Major Potential Hazard, Moderate plausibility.

The use of laxatives is contraindicated in patients with inflammatory bowel disease. Patients with inflammatory bowel disease may experience colonic perforation with use of stimulant laxatives.

References

  1. "Product Information. Fleet Bisacodyl Enema (bisacodyl)." Fleet, Lynchburg, VA.
  2. "Product Information. Dulcolax (bisacodyl)." Ciba Self-Medication Inc, Woodbridge, NJ.
Major

Laxatives (applies to chromium picolinate/inulin) intestinal obstruction disorders

Major Potential Hazard, Moderate plausibility. Applicable conditions: Gastrointestinal Obstruction

The use of laxatives is contraindicated in patients with intestinal obstruction disorders. Patients with intestinal obstruction disorders may need their underlying condition treated to correct the constipation. Some laxatives require reduction in the colon to their active form to be effective which may be a problem in patients with intestinal obstruction.

References

  1. "Product Information. Kondremul (mineral oil)." Bristol-Myers Squibb, Princeton, NJ.
  2. "Product Information. Fleet Bisacodyl Enema (bisacodyl)." Fleet, Lynchburg, VA.
  3. "Product Information. Dulcolax (bisacodyl)." Ciba Self-Medication Inc, Woodbridge, NJ.
  4. "Product Information. Fleet Mineral Oil Enema (mineral oil)." Fleet, Lynchburg, VA.
  5. "Product Information. Fleet Babylax (glycerin)." Alcon Laboratorries Inc, Fort Worth, TX.
View all 5 references
Moderate

Chromium/selenium/zinc (applies to chromium picolinate/inulin) renal dysfunction

Moderate Potential Hazard, Moderate plausibility.

The trace metals, chromium and zinc, are excreted primarily in the urine. Selenium is partially excreted in the urine. Supplemental doses of these agents may need to be adjusted, reduced, or omitted in patients with renal dysfunction.

References

  1. "Product Information. Chroma-Pak (chromic chloride)." Abbott Pharmaceutical, Abbott Park, IL.
  2. "Product Information. Sele-Pak (selenious acid)." Fujisawa, Deerfield, IL.
  3. "Product Information. Galzin (zinc acetate)." Teva Pharmaceuticals USA, North Wales, PA.
Moderate

Trace metals (applies to chromium picolinate/inulin) malabsorption syndromes

Moderate Potential Hazard, Moderate plausibility.

The trace metals manganese, chromium, copper, selenium, and zinc are absorbed in the GI tract from dietary sources and following administration of oral supplements. GI absorption may be decreased in patients with malabsorption syndromes. Therefore, larger dosages may be required when these supplements are given orally. Parenteral administration may be appropriate.

References

  1. "Product Information. Chroma-Pak (chromic chloride)." Abbott Pharmaceutical, Abbott Park, IL.
  2. "Product Information. Galzin (zinc acetate)." Teva Pharmaceuticals USA, North Wales, PA.
  3. "Product Information. Manganese Chloride (manganese chloride)." Abbott Pharmaceutical, Abbott Park, IL.
  4. "Product Information. Sele-Pak (selenious acid)." Fujisawa, Deerfield, IL.
  5. "Product Information. Manganese Sulfate (manganese sulfate)." American Regent Laboratories Inc, Shirley, NY.
  6. "Product Information. Copper Sulfate (copper sulfate)." Humco Holding Group, Texarkana, TX.
View all 6 references

Chromium picolinate / inulin drug interactions

There are 72 drug interactions with chromium picolinate / inulin

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.